

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

PFIZER INC., C.P. PHARMACEUTICALS)	
INTERNATIONAL C.V., PF PRISM C.V.,)	
PBG PUERTO RICO LLC and PF PRISM)	
IMB B.V.,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. _____
)	
DEXCEL PHARMA TECHNOLOGIES)	
LTD.,)	
)	
Defendant.)	

COMPLAINT

Pfizer Inc., C.P. Pharmaceuticals International C.V., PF PRISM C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. (collectively “Plaintiffs” or “Pfizer”), for their Complaint against Dexcel Pharma Technologies Ltd. (“Defendant” or “Dexcel”), allege as follows:

NATURE OF THE ACTION

1. This is an action by Pfizer against Dexcel for infringement of United States Patent No. RE41,783 (“the RE’783 patent”).
2. This action arises out of Dexcel’s filing of Abbreviated New Drug Application (“ANDA”) No. 218668, seeking approval by the United States Food and Drug Administration (“FDA”) to sell generic copies of Pfizer’s Xeljanz® XR, 11 mg and 22 mg (tofacitinib citrate extended-release tablets), prior to the expiration of the RE’783 patent. Dexcel’s proposed extended-release tofacitinib citrate 11 mg and 22 mg products are referred to as “Dexcel Generic XR Tablets.”

THE PARTIES

3. Plaintiff Pfizer Inc. is a corporation organized and existing under the laws of the State of Delaware and having a place of business at 66 Hudson Boulevard, New York, NY 10001.

4. Plaintiff C.P. Pharmaceuticals International C.V. is a limited partnership (*commanditaire vennootschap*) organized under the laws of the Netherlands, having its business address at Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, the Netherlands. Pfizer Inc. is the ultimate parent company of C.P. Pharmaceuticals International C.V.

5. Plaintiff PF PRISM C.V. is a limited partnership (*commanditaire vennootschap*) organized under the laws of the Netherlands, having its registered seat in Rotterdam, the Netherlands, having its business address at Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, the Netherlands, and registered at the Trade Register held by the Chamber of Commerce in Rotterdam, the Netherlands, under number 51840456. Pfizer Inc. is the ultimate parent company of PF PRISM C.V.

6. Plaintiff PBG Puerto Rico LLC is a limited liability company organized and existing under the laws of Puerto Rico and having its business address at Professional Offices Park V, 996 San Roberto Street, 4th Floor, San Juan, Puerto Rico 00926. Pfizer Inc. is the ultimate parent company of PBG Puerto Rico LLC.

7. Plaintiff PF PRISM IMB B.V. is a private limited liability company (*besloten vennootschap*) organized under the laws of the Netherlands, having its registered seat in Rotterdam, the Netherlands, and having its business address at Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, the Netherlands. Pfizer Inc. is the ultimate parent company of PF PRISM IMB B.V.

8. On information and belief, defendant Dexcel Pharma Technologies Ltd. is a company organized and existing under the laws of Israel, having its registered office at 21 Nahum Haftzadi, Jerusalem, 9548402, Israel.

JURISDICTION AND VENUE

9. This action arises under the patent laws of the United States, Title 35, United States Code. The Court has subject matter jurisdiction over this action pursuant to the provisions of 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

10. This Court has personal jurisdiction over Dexcel by virtue of the fact, *inter alia*, that Dexcel has committed a tortious act of patent infringement that has led and/or will lead to foreseeable harm and injury to Pfizer throughout the United States, including in the State of Delaware. In particular, this suit arises out of Dexcel's filing of ANDA No. 218668 seeking FDA approval to sell Dexcel Generic XR Tablets prior to the expiration of the RE'783 patent throughout the United States, including in Delaware.

11. On information and belief, if ANDA No. 218668 is approved, Dexcel Generic XR Tablets will, among other things, be marketed and distributed by Dexcel in Delaware, prescribed by physicians practicing in Delaware, dispensed by pharmacies located in Delaware, and/or used by patients in Delaware.

12. Dexcel's infringing activities with respect to its filing of ANDA No. 218668 and its intent to commercialize and sell Dexcel Generic XR Tablets prior to the expiration of the RE'783 patent have led and/or will lead to foreseeable harm and injury to Plaintiffs, including Pfizer Inc., which is incorporated in Delaware.

13. In the alternative, this Court has personal jurisdiction over Dexcel Pharma Limited under Federal Rule of Civil Procedure 4(k)(2). Dexcel Pharma Limited has contacts with the United States by virtue, *inter alia*, of its filing ANDA No. 218668 with the FDA.

14. Venue is proper in this judicial district pursuant to 28 U.S.C. § 1391. As a foreign corporation, Dexcel may be sued in any judicial district pursuant to 28 U.S.C. § 1391(c)(3).

BACKGROUND

Xeljanz XR

15. The active ingredient in Pfizer's Xeljanz XR product is tofacitinib citrate. Xeljanz XR contains tofacitinib citrate in amounts equivalent to 11 mg and 22 mg of tofacitinib base in extended-release tablets formulated for once-daily administration.

16. The FDA-approved Prescribing Information for Xeljanz XR states that tofacitinib citrate has the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino)- β -oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1).

17. Tofacitinib citrate is an inhibitor of Janus kinases ("JAKs") and is indicated, *inter alia*, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more Tumor Necrosis Factor ("TNF") blockers, for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to TNF blockers, and for the treatment of adult patients with moderately to severely active ulcerative colitis who have an inadequate response or who are intolerant to TNF blockers.

Orange Book Listing for Xeljanz XR

18. Pfizer Inc. holds approved New Drug Application ("NDA") No. 208246 for EQ 11 mg and 22 mg base tofacitinib citrate extended-release tablets, which it sells under the registered name Xeljanz XR. The Xeljanz XR tablets are approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

19. Pursuant to 21 U.S.C. § 355(b)(1) and the regulations the FDA has promulgated pursuant thereto, the RE'783 patent is listed in the FDA publication titled "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book") for the Xeljanz XR NDA.

20. The Orange Book lists the expiration date for the RE'783 patent as December 8, 2025.

21. The Orange Book lists four additional patents for Xeljanz XR that are not at issue: U.S. Patent No. 6,965,027 (expired March 25, 2023), U.S. Patent No. 9,937,181¹ (expiring March 14, 2034), U.S. Patent No. 10,639,309² (expiring March 14, 2034), and U.S. Patent No. 11,253,523 (expiring March 14, 2034).

The RE'783 Patent

22. On September 28, 2010, the United States Patent and Trademark Office ("USPTO") issued the RE'783 patent, titled "Pyrrolo[2,3-d]pyrimidine Compounds." The RE'783 patent is a reissue of U.S. Patent No. 6,627,754, which issued on September 30, 2003. The RE'783 patent is duly and legally assigned to Pfizer Inc. A copy of the RE'783 patent is attached hereto as Exhibit A.

23. On December 14, 2016, the USPTO issued a Notice of Final Determination extending the expiration date of the RE'783 patent to December 8, 2025.

24. C.P. Pharmaceuticals International C.V. is the exclusive licensee of the RE'783 patent.

¹ Listed for the 11 mg formulation.

² Listed for the 22 mg formulation.

25. C.P. Pharmaceuticals International C.V. conveyed rights under the RE’783 patent to Pfizer Pharmaceuticals LLC, PF PRISM C.V., and Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V.

26. Pfizer Pharmaceuticals LLC has conveyed its rights to the RE’783 patent to PBG Puerto Rico LLC.

27. Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V. has conveyed its rights to the RE’783 patent to PF PRISM IMB B.V.

Dexcel’s ANDA

28. By letter dated September 29, 2023, and received by Pfizer on or around October 2, 2023 (the “Dexcel Notice Letter”), Dexcel notified Pfizer that it had submitted ANDA No. 218668 to the FDA, seeking approval under the Federal Food, Drug and Cosmetic Act to market and sell Dexcel Generic XR Tablets—generic copies of Xeljanz XR (tofacitinib citrate EQ 11 mg and 22 mg base extended-release tablets)—prior to the expiration of the RE’783 patent.

29. The Dexcel Notice Letter describes the Dexcel Generic XR Tablets as “tofacitinib, extended release tablet, 11 mg, 22 mg.”

30. The Dexcel Notice Letter states that Dexcel has filed ANDA No. 218668 seeking approval to “engage in the commercial manufacture, use, or sale” of Dexcel Generic XR Tablets prior to the expiration of the RE’783 patent.

31. The Dexcel Notice Letter asserts that ANDA No. 218668 contains a Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A) alleging that the RE’783 patent is “invalid, unenforceable, and/or will not be infringed by the manufacture, use, or sale” of Dexcel Generic XR Tablets.

32. Attached to the Dexcel Notice Letter was Dexcel’s Detailed Statement of the Factual and Legal Bases for Dexcel Pharma Technologies Ltd.’s Opinion that United States Patent

Nos. RE41,783; 9,937,181; 10,639,309 and 11,253,523 Are Invalid, Unenforceable and/or Will Not Be Infringed (“Dexcel’s Detailed Statement”) asserting, among other things, the purported factual and legal bases for Dexcel’s contention that the claims of the RE’783 patent are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, or offer for sale in the United States or importation into the United States of Dexcel Generic XR Tablets.

33. Dexcel’s Detailed Statement alleges that all claims of the RE’783 patent are invalid. Dexcel’s Detailed Statement does not contain a noninfringement argument with respect to the RE’783 patent.

34. On information and belief, upon approval of ANDA No. 218668, Dexcel will sell and distribute Dexcel Generic XR Tablets in the United States.

COUNT I
(Infringement of the RE’783 Patent by Dexcel Generic XR Tablets)

35. The allegations of paragraphs 1-34 above are repeated and re-alleged as if set forth fully herein.

36. Pursuant to 35 U.S.C. § 271(e)(2)(A), Dexcel’s filing of ANDA No. 218668 seeking approval to market and sell Dexcel Generic XR Tablets before the expiration of the RE’783 patent was an act of infringement of at least claim 4 of the RE’783 patent, entitling Pfizer to the relief provided by 35 U.S.C. § 271(e)(4), including, *inter alia*, an order of this Court that the effective date of approval for ANDA No. 218668 be a date which is not earlier than the expiration date of the RE’783 patent.

37. Dexcel had knowledge of the RE’783 patent when it submitted ANDA No. 218668 to the FDA.

38. On information and belief, upon FDA approval of ANDA No 218668, Dexcel intends to engage in the manufacture, use, offer for sale, sale, and/or importation of Dexcel Generic

XR Tablets in the United States and will thereby directly infringe at least claim 4 of the RE'783 patent under 35 U.S.C. § 271(a).

39. The foregoing actions by Dexcel constitute and/or would constitute infringement of at least claim 4 of the RE'783 patent.

40. Pfizer will be substantially and irreparably harmed if Dexcel is not enjoined from infringing the RE'783 patent. Pfizer has no adequate remedy at law.

PRAYER FOR RELIEF

WHEREFORE, Pfizer requests the following relief:

- A. A judgment that Dexcel's submission of ANDA No. 218668 was an act of infringement and that Dexcel's making, using, offering to sell, selling, or importing Dexcel Generic XR Tablets in the United States prior to the expiration of the RE'783 patent will directly infringe that patent;
- B. A judgment that the effective date of any FDA approval for Dexcel to make, use, offer for sale, sell, market, distribute, or import Dexcel Generic XR Tablets into the United States be no earlier than the date on which the RE'783 patent expires, or the later expiration of any exclusivity to which Pfizer is or becomes entitled;
- C. A permanent injunction enjoining Dexcel, its officers, agents, servants, and employees, and those persons in active concert or participation with any of them, from making, using, selling, offering for sale, marketing, distributing, or importing Dexcel Generic XR Tablets into the United States, and from inducing or contributing to any of the foregoing, prior to the expiration of the RE'783 patent, or the later expiration of any exclusivity to which Pfizer is or becomes entitled;

- D. A judgment that this case is an exceptional case under 35 U.S.C. § 285, entitling Pfizer to an award of its reasonable attorneys' fees for bringing and prosecuting this action;
- E. An award of Pfizer's costs and expenses in this action; and
- F. Such further and additional relief as this Court deems just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Megan E. Dellinger

OF COUNSEL:

Aaron Stiefel
Daniel P. DiNapoli
Michael Sapiro
ARNOLD & PORTER KAYE SCHOLER LLP
250 West 55th Street
New York, NY 10019-9710
(212) 836-8000

Soumitra Deka
DLA PIPER LLP (US)
555 Mission Street, Suite 2400
San Francisco, CA 94105-2933
(415) 836-2500

November 15, 2023

Jack B. Blumenfeld (#1014)
Megan E. Dellinger (#5739)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
mdellinger@morrisnichols.com

Attorneys for Plaintiffs